Alliance Global Partners Issues Pessimistic Forecast for Vivos Therapeutics (NASDAQ:VVOS) Stock Price

Vivos Therapeutics (NASDAQ:VVOS) had its price objective lowered by stock analysts at Alliance Global Partners from $8.25 to $6.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Alliance Global Partners’ price target points to a potential upside of 107.61% from the stock’s current price.

Separately, Ascendiant Capital Markets lifted their price objective on Vivos Therapeutics from $6.40 to $6.60 and gave the stock a “buy” rating in a research note on Tuesday, August 20th.

Vivos Therapeutics Stock Up 2.1 %

NASDAQ VVOS opened at $2.89 on Tuesday. The company has a market capitalization of $13.99 million, a price-to-earnings ratio of -0.51 and a beta of 7.71. Vivos Therapeutics has a twelve month low of $1.91 and a twelve month high of $48.79. The stock has a fifty day simple moving average of $2.78 and a 200 day simple moving average of $2.52.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.